Hoshida Tadafumi, Tanabe Kazufumi, Tsubaki Masanobu, Nagai Noriaki, Nishida Shozo
Department of Pharmacy, Japanese Red Cross Wakayama Medical Center, Wakayama, JPN.
Laboratory of Pharmacotherapy, Kagawa School of Pharmaceutical Sciences, Tokushima Bunri University, Sanuki, JPN.
Cureus. 2025 Jul 2;17(7):e87184. doi: 10.7759/cureus.87184. eCollection 2025 Jul.
Anti-epidermal growth factor receptor (anti-EGFR) antibodies are used to treat colorectal cancer. The incidence of side effects is higher in patients who receive re-administration than in those who were initially introduced. In this report, we describe three cases. Case 1 involved a woman in her 70s. Compared with the initial administration, skin rash, skin dryness, and stomatitis grades were observed to be high. Finally, the patient was diagnosed with progressive disease (PD) after five months, which was shorter than that at the time of initial administration. Case 2 involved a man in his 70s, who was restarted on panitumumab monotherapy. Approximately one month after re-administration, the patient developed early grade 3 skin symptoms and hypomagnesemia, peaking at 0.8 mg/dL. Finally, the patient was diagnosed with PD after approximately six months, which was shorter than that at the time of initial administration. Case 3 involved a man in his 30s. After resuming the same treatment, the patient developed paronychia up to grade 3, which continued for approximately two years with dermatological intervention. In the ambulatory therapy center, multi-disciplinary medical staff are involved in the prevention of serious complications. Early intervention and patient education regarding the adverse effects connected with re-administration are essential.
抗表皮生长因子受体（anti-EGFR）抗体用于治疗结直肠癌。再次给药的患者副作用发生率高于初次使用的患者。在本报告中，我们描述了三例病例。病例1为一名70多岁的女性。与初次给药相比，观察到皮疹、皮肤干燥和口腔炎的分级更高。最后，患者在五个月后被诊断为疾病进展（PD），这比初次给药时的时间短。病例2为一名70多岁的男性，重新开始帕尼单抗单药治疗。再次给药后约一个月，患者出现早期3级皮肤症状和低镁血症，最低降至0.8mg/dL。最后，患者在约六个月后被诊断为PD，这比初次给药时的时间短。病例3为一名30多岁的男性。恢复相同治疗后，患者出现了高达3级的甲沟炎，在皮肤科干预下持续了约两年。在门诊治疗中心，多学科医务人员参与预防严重并发症。对于再次给药相关的不良反应进行早期干预和患者教育至关重要。
